Most Read Articles
Elvira Manzano, 28 Jul 2020
The efficacy and cardiovascular (CV) safety of the SGLT2* inhibitor empagliflozin vs DPP-4** inhibitors and GLP-1*** receptor agonists in real-world patients were demonstrated in two interim analyses of the EMPRISE+ study presented at ADA 2020.
Roshini Claire Anthony, 3 days ago

Patients hospitalized with mild-to-moderate COVID-19 who are on angiotensin-converting enzyme (ACE) inhibitors or angiotensin receptor blockers (ARBs) for hypertension should continue these medications, according to primary results of the BRACE CORONA trial presented at ESC 2020.

Tristan Manalac, 09 Jul 2020
Left ventricular assist devices (LVADs) trigger almost immediate favourable metabolic changes in both diabetics and nondiabetics, according to a recent study.
Tristan Manalac, 04 Sep 2020
Anticoagulation therapy may be of value to patients with new-onset atrial fibrillation (AF) associated with sepsis, easing the risk of all-cause mortality and ischaemic stroke without increasing the likelihood of major bleeding, reports a study presented at the Digital 2020 Congress of the European Society of Cardiology (ESC).

Myocardial injury ups risk of death in COVID-19 patients

06 Aug 2020

Myocardial injury appears to frequently occur among hospitalized patients with the novel coronavirus disease (COVID-19), whereas troponin concentrations remain at low levels, according to a US study. Patients with cardiovascular disease (CVD) have a higher likelihood of myocardial injury than those without CVD.

“Troponin elevation among patients hospitalized with COVID-19 is associated with higher risk of mortality,” the investigators noted.

This study sought to describe the degree of myocardial injury and associated outcomes in a large hospitalized cohort with laboratory-confirmed COVID-19.

The investigators analysed 2,736 patients with COVID-19 (median age, 66.4 years; 59.6 percent men) admitted to one of five Mount Sinai Health System hospitals in New York City, US, between 27 February 2020 and 12 April 2020, with troponin-I (normal value <0.03 ng/ml) measured within 24 h of admission. Electronic health records were utilized to obtain patient demographics, medical histories, admission laboratory results, and outcomes.

CVDs, such as coronary artery disease, atrial fibrillation, and heart failure, as well as hypertension and diabetes, were common in patients with higher troponin concentrations. Of the patients, 985 (36 percent had elevated troponin concentrations and 506 (18.5 percent) died during hospitalization.

Adjustments for disease severity and relevant clinical factors demonstrated that even small amounts of myocardial injury (eg, troponin I >0.03–0.09 ng/ml; n=455; 16.6 percent) could result in death (adjusted hazard ratio [HR], 1.75, 95 percent confidence interval [CI], 1.37–2.24; p<0.001), while greater amounts (troponin I >0.09 ng/dl; n=530; 19.4 percent) significantly correlated with a much higher risk (adjusted HR, 3.03, 95 percent CI, 2.42–3.80; p<0.001).

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Cardiology - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Elvira Manzano, 28 Jul 2020
The efficacy and cardiovascular (CV) safety of the SGLT2* inhibitor empagliflozin vs DPP-4** inhibitors and GLP-1*** receptor agonists in real-world patients were demonstrated in two interim analyses of the EMPRISE+ study presented at ADA 2020.
Roshini Claire Anthony, 3 days ago

Patients hospitalized with mild-to-moderate COVID-19 who are on angiotensin-converting enzyme (ACE) inhibitors or angiotensin receptor blockers (ARBs) for hypertension should continue these medications, according to primary results of the BRACE CORONA trial presented at ESC 2020.

Tristan Manalac, 09 Jul 2020
Left ventricular assist devices (LVADs) trigger almost immediate favourable metabolic changes in both diabetics and nondiabetics, according to a recent study.
Tristan Manalac, 04 Sep 2020
Anticoagulation therapy may be of value to patients with new-onset atrial fibrillation (AF) associated with sepsis, easing the risk of all-cause mortality and ischaemic stroke without increasing the likelihood of major bleeding, reports a study presented at the Digital 2020 Congress of the European Society of Cardiology (ESC).